{
    "organizations": [],
    "uuid": "5b6109d3f50246792b314c8927d4fba14e431676",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-spring-bank-pharmaceuticals-report/brief-spring-bank-pharmaceuticals-reports-q4-loss-per-share-0-11-idUSASB0C6JM",
    "ord_in_thread": 0,
    "title": "BRIEF-Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Spring Bank Pharmaceuticals Inc:\n* SPRING BANK PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATIONAL RESULTS\n* Q4 LOSS PER SHARE $0.11 * SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 2019\n* SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR\n* SPRING BANK PHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $50.6 MILLION AS OF DEC 31, 2017, COMPARED TO $25.5 MILLION AS OF DEC 31, 2016 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-21T05:35:00.000+02:00",
    "crawled": "2018-02-21T21:21:41.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "spring",
        "bank",
        "pharmaceutical",
        "inc",
        "spring",
        "bank",
        "pharmaceutical",
        "provides",
        "corporate",
        "update",
        "report",
        "fourth",
        "quarter",
        "financial",
        "operational",
        "result",
        "q4",
        "loss",
        "per",
        "share",
        "spring",
        "bank",
        "pharma",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "dec",
        "fund",
        "operating",
        "expense",
        "capital",
        "expenditure",
        "requirement",
        "q4",
        "spring",
        "bank",
        "pharma",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "dec",
        "sufficient",
        "fund",
        "initiation",
        "phase",
        "trial",
        "inarigivir",
        "spring",
        "bank",
        "pharma",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "dec",
        "compared",
        "million",
        "dec",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}